GW Pharmaceuticals CEO after new drug launch: it’s ‘important to distinguish between what’s medicine and what’s not’ in cannabis

Now, physicians have a level of “assurance” that if they prescribe Epidiolex [GW Pharmaceutical’s CBD], they’re giving patients a federally-sanctioned, standardized form of medication, the CEO said. “We think it’s’ really important to distinguish between what is medicine and what is not.” “They know exactly what is in it, they understand the dosing, they understand its…

READ MORE
Politics

The future doesn’t look too bright for Insys

Insys’ (INSY) past is in the news again; a past it wishes it could forget. In a 20-page report with a 173-page appendix consisting mostly of distasteful emails depicting aggressive sales tactics for an opiate 30 times more powerful than heroin, the Senate… released the details of a… case against the company… The company’s main income is…

READ MORE
Modern Culture

Psilocybin initiative moves to signature-gathering stage for May 2019

On October 5, 2018, they got the go-ahead to begin signature-gathering. Signature-gatherers will have forms ready for prospective signers explaining the medical benefits and offering clinical information about psilocybin. The Denver initiative focuses on psilocybin mushrooms, which it defines as “fungal matter containing psilocybin, psilocin, baeocystin, or nor-baeocystin.” … Currently, the only way to legally consume…

READ MORE

FDA death data on kratom linked to adulterated products, not the kratom plant itself

“The FDA appears to be deliberately violating the provisions of the Information Quality Act by widely disseminating incomplete, inaccurate, biased, and unreproducible information to local medical examiners and coroners, incorrectly blaming kratom for deaths that were actually caused by polydrug use or deliberately adulterated kratom products.” NIDA’s conclusion following its extensive review of whether a…

READ MORE